Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 11, 2025Journal of Health Science and Medical ResearchOpen Access

In Vitro Synergistic Activity of Fosfomycin-Colistin Combination Against Carbapenem-Resistant Pseudomonas Aeruginosa from Ventilator-Associated Pneumonia Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

ACArnon ChukamnerdOPOrawan PhetsrithongRSRosesathorn Soontarach

Discussion

Loading...

Member takes

Overview

Cross-sectional analysis shows limited synergy of fosfomycin and colistin in clinical isolates from VAP patients, suggesting challenges in treatment.

Key Points

  • Synergistic activity of fosfomycin and colistin against CRPA was rarely observed, affecting treatment options.
  • Only 5% of the tested CRPA isolates demonstrated synergy, highlighting treatment limitations.
  • The evaluation was conducted retroactively on 40 VAP patients with CRPA infections, gathering crucial insights into resistance profiles.
  • Further studies are necessary to assess the clinical relevance of this antibiotic combination for severe infections.

Cite This Study

Chukamnerd et al. (2025) studied this question.

synapsesocial.com/papers/68c2354db210217d6476fca7https://doi.org/10.31584/jhsmr.20251241
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1In-vitro Susceptibility of Fosfomycin Against XDR – <i>Klebsiella pneumoniae</i> Isolated from Urine2025
  2. 2Comparison of different colistin sulfate regimens for carbapenem-resistant gram-negative bacteria pneumonia in neurocritical care patients: a retrospective cohort study2025
  3. 3Activity of ceftazidime-avibactam combinations against carbapenem-resistant Klebsiella pneumoniae assessed by checkerboard method2025
  4. 4A Tentative Clinical Study: Colistin Combined with Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infection2025 · 2 citations
  5. 5Efficacy and Safety of Three Colistin Regimens in the Treatment of Nosocomial Pneumonia Caused by Carbapenem-Resistant Organisms: A Single Centre, Open Label, Prospective Cohort Study2025